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ABSTRACT
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin’s lymphoma 
(NHL). In cancers, tumor suppressive microRNAs may be silenced by DNA 
hypermethylation. By microRNA profiling of representative EBV-negative MCL cell 
lines before and after demethylation treatment, miR-155-3p was found significantly 
restored. Methylation-specific PCR, verified by pyrosequencing, showed complete 
methylation of miR-155-3p in one MCL cell line (REC-1). 5-aza-2′-deoxycytidine 
treatment of REC-1 led to demethylation and re-expression of miR-155-3p. Over-
expression of miR-155-3p led to increased sub-G1 apoptotic cells and reduced 
cellular viability, demonstrating its tumor suppressive properties. By luciferase assay, 
lymphotoxin-beta (LT-β) was validated as a miR-155-3p target. In 31 primary MCL, 
miR-155-3p was found hypermethylated in 6(19%) cases. To test if methylation of 
miR-155-3p was MCL-specific, miR-155-3p methylation was tested in an additional 
191 B-cell, T-cell and NK-cell NHLs, yielding miR-155-3p methylation in 66(34.6%) 
including 36(27%) non-MCL B-cell, 24(53%) T-cell and 6(46%) of NK-cell lymphoma. 
Moreover, in 72 primary NHL samples with RNA, miR-155-3p methylation correlated 
with miR-155-3p downregulation (p=0.024), and LT-β upregulation (p=0.043). 
Collectively, miR-155-3p is a potential tumor suppressive microRNA hypermethylated 
in MCL and other NHL subtypes. As miR-155-3p targets LT-β, which is an upstream 
activator of the non-canonical NF-kB signaling, miR-155-3p methylation is potentially 
important in lymphomagenesis.
INTRODUCTION
Mantle cell lymphoma (MCL) is a rare but 
aggressive B-cell tumor accounting for 4%-6% of all 
non-Hodgkin’s lymphomas (NHLs) [1-4]. It is 
distinguished from other NHLs by the genetic hallmark of 
t(11;14)(q13;32) translocation which leads to constitutive 
over-expression of cyclinD1 (CCND1) [1, 2, 5]. Other 
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chromosomal losses reported in MCL include del(9p21), 
which encodes two tumor suppressive genes p16INK4a and 
ARF crucial for regulating cell cycle, in aggressive MCL 
cases [6, 7].
Unlike inactivating mutation of tumor suppressive 
genes, DNA methylation leads to reversible gene 
silencing mediated by the addition of a methyl group 
to the carbon 5 position of the cytosine ring in a CpG 
dinucleotide without changing of DNA sequence. Cancers 
are characterized by global DNA hypomethylation 
but locus-specific hypermethylation, particularly in 
promoter-associated CpG islands, leading to silencing of 
the downstream genes or non-protein-coding microRNAs 
[8-11]. Moreover, DNA methylation of genes or 
microRNAs may carry prognostic impacts in certain 
cancers including NHL [12, 13].
MicroRNAs are short, single-stranded, and non-
protein-coding RNAs of 19-25 nucleotides [14]. Sequence-
specific binding of a microRNA to 3′-untranslated region 
(3′-UTR) of its target protein-coding gene mRNA will 
result in translational block, and hence gene repression. We 
have previously reported methylation-silencing of several 
tumor suppressive microRNAs including miR-129-2, miR-
203 and miR-124-1 in different types of haematological 
neoplasms, including B-, T- and NK-cell lymphoma 
[15-17]. However, data on the role DNA methylation-
mediated silencing of tumor suppressive microRNA in 
MCL and other NHL subtypes remains scanty.
In this study, we attempted to identify tumor 
suppressive microRNAs potentially hypermethylated 
in MCL by studying microRNA expression profiles 
of representative EBV-negative MCL cell lines before 
and after treatment with 5-azadC, in which miR-155-3p 
emerged as an important candidate. Subsequent studies 
verified methylation of miR-155-3p in MCL cell lines 
and primary MCL samples, resulting in upregulation of 
lymphotoxin-beta (LT-β), which is a miR-155-3p direct 
target. To test if miR-155-3p methylation is MCL-specific, 
miR-155-3p methylation was studied in an additional 191 
B- (other than MCL), T- and NK-cell lymphomas, which 
showed prevalent miR-155-3p methylation across multiple 
NHL subtypes. Moreover, in primary NHL samples with 
both DNA and RNA, miR-155-3p methylation correlated 
with repression of miR-155-3p and upregulation of 
LT-β. Since LT-β is a positive regulator of non-canonical 
NF-kB signaling, miR-155-3p methylation is implicated in 
lymphomagenesis.
RESULTS
Methylation-mediated silencing of miR-155-3p  
in MCL cell lines
MINO and JEKO-1 cells, before and after 
treatment with 1.5uM of 5-azadC, were subjected to high-
throughput microarray detecting a total of the 754 known 
microRNAs. Upon 5-azadC treatment, expression of 26 and 
44 microRNAs were found upregulated by ≥ 2.5-fold in 
MINO and JEKO-1 respectively (Supplementary Table 1). 
One of the most upregulated microRNAs was  miR-155-
3p, which showed a 33-fold upregulation in MINO. By 
studying methylation status of the promoter region of its 
host gene, MIR155HG (Figure 1A), methylation was absent 
in healthy buffy coat and tonsil controls by MSP (Figure 
1B). By MSP, complete methylation was detected in REC-
1, one of the four MCL cell lines. Moreover, the methylation 
status detected by MSP was verified by quantitative 
pyrosequencing, which showed an average methylation 
frequency of <10% in completely unmethylated normal 
controls (buffy coat from healthy blood donor and normal 
tonsils) and completely unmethylated cell lines. By 
contrast, an average methylation frequency of >90% was 
detected in REC-1 which was completely methylated by 
MSP (Figure 1C). Since REC-1 was completely methylated, 
this cell line was treated with different concentrations of 
5-azadC for 3 days to investigate if demethylation could 
restore expression of miR-155-3p. Treatment with 5-azadC 
resulted in a dose-dependent demethylation as measured 
by pyrosequencing (Figure 2A) and emergence of U-MSP 
amplification by MSP (data not shown). Importantly, miR-
155-3p expression was restored accordingly upon treatment 
indicating the reversible gene silencing of this microRNA 
(Figure 2B).
Tumor suppressive function of miR-155-3p 
in MCL
To study the biological function of miR-155-3p in 
MCL, miR-155-3p was over-expressed in REC-1 followed 
by trypan blue exclusion assay (Figure 3A) and cell 
cycle analysis (Figure 3B). Restoration of miR-155-3p  
expression led to decreased number of viable cells by 
10% (p=0.004) as detected by trypan blue staining and 
increased Sub-G1 apoptotic cells by 4.4-fold (p=0.007) 
as demonstrated by cell cycle analysis compared with 
cells transfected with non-targeting scramble control. 
Therefore, miR-155-3p might function as a tumor 
suppressive microRNA in MCL.
LT-β targeted by miR-155-3p
To identify protein-coding genes (PCGs) targeted 
by miR-155-3p, bioinformatic analysis of the 3′-UTR 
of PCGs using 3 databases (miR-DB, RNA22 and 
miRanda) was performed. In brief, the putative target 
fulfilled the following criteria: (1) it was detected as 
putative target in all three databases, (2) it has been 
reported to play a role in B-cell development and was 
found overexpressed in MCL, other NHL subtypes or 
other cancers, (3) it was a positive regulator that led to 
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Figure 1: Methylation of miR-155-3p in mantle cell lymphoma (MCL) cell lines. (A) Schematic diagram showing the exons 
(solid box) and CpG island (black lollipop) located 190bp upstream to the transcription start site (TSS) of MIR155HG which is the host 
gene for miR-155-3p. Primers for methylation-specific PCR (MSP) and quantitative pyrosequencing were designed to study that CpG 
island. (B) Methylation pattern in 6 normal buffy coats, 15 normal tonsils and 4 MCL cell lines by MSP detecting methylated [M] and 
unmethylated [U] allele separately. Complete methylation in REC-1 was detected by presence of M-MSP signal only. (C) Pyrograms of 
normal buffy coat, normal tonsil and 4 MCL cell lines measuring average methylation percentage of 6 consecutive CpG sites.
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Figure 2: Tumor-specific methylation leads to silencing of miR-155-3p in REC-1 cells. (A) Pyrograms of 5-azadC treated 
REC-1 cells for three days at concentrations of 0, 0.5 or 1uM. (B) RT-qPCR of REC-1 receiving 5-azadC treatment measuring expression 
of miR-155-3p.
Figure 3: Tumor suppressive function of miR-155-3p. REC-1 cells overexpressed with miR-155-3p for 24hours (A) Trypan blue 
staining to measure cell viability and (B) 7-AAD staining for cell cycle analysis.
activation of signaling pathways that were activated in 
MCL (e.g. NF-kB, ERK and AKT) or in other cancers, 
and (4) the target had a typical 7-8mer (8mer, 7mer-m8, 
7mer-A1) match to the miR-155-3p seed region as 
predicted by the databases. LT-β appeared in all 
3 databases as one of the best targets for the miR-155-3p. 
By studying the sequence alignment, the 3′-UTR of 
LT-β contains 1 sequence motif that perfectly matched 
with the seed region of the miR-155-3p (i.e. nts 2-9 
at the 5′-end of the mature microRNA) (Figure 4A).  
Restoration of miR-155-3p in REC-1 led to 
downregulation of LT-β expression at both RNA (by 
RT-qPCR; Figure 4B) and protein level (by flow 
cytometry; Figure 4C), suggesting that LT-β expression 
was repressed by miR-155-3p.
Therefore, luciferase reporter assay was performed 
to validate if LT-β is a direct target of miR-155-3p.  
Co-transfection of a luciferase reporter construct, 
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Figure 4: Direct regulation of LT-β by miR-155-3p through complementarity to 3′-UTR of LT-β. (A) Sequence alignment 
of miR-155-3p seed sequences with the binding region of the LT-β 3′-UTR. The 3′-UTR sequence of the wild-type (LTB 3′-UTR Wild-
type) or the 7bp-deletion mutant (LTB 3'-UTR Deletion) cloned into luciferase plasmid was depicted. Expression analysis of LT-β in REC-1 
cells overexpressed with miR-155-3p by (B) RT-qPCR and (C) flow cytometry. (D) Luciferase reporter assay using luciferase plasmid 
carrying wild-type (WT) or deleted binding site (LTB-Deleted) of LT-β 3′UTR co-transfected with miR-155-3p as compared with scramble 
nucleotide control in HeLa cells.
containing a wild-type 3′-UTR sequence of the LT-β, with 
miR-155-3p resulted in loss of luciferase activity by 40% 
as compared with non-targeting scramble oligonucleotides 
(Figure 4D). Conversely, the luciferase activity was fully 
rescued when a mutant luciferase reporter, which carried 
a deletion of the seed region binding site of miR-155-
3p, was co-transfected with miR-155-3p. These findings 
collectively suggested the direct binding and inhibition of 
the LT-β 3′-UTR by miR-155-3p.
Methylation-mediated silencing of miR-155-3p in 
MCL and other NHL patients
In the 31 primary MCL samples, aberrant 
methylation was also found in 6(19.4%) cases, 
suggesting a pathological relevance of methylation-
mediated silencing of miR-155-3p (Figure 5A). 
To study if miR-155-3p methylation was restricted 
to the MCL, which carried the characteristic 
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t(11;14)(q13;32) translocation, miR-155-3p  
methylation was also studied in a panel of NHLs other than 
MCL, which comprised 133 non-MCL B-cell, 45 T-cell 
and 13 NK-cell neoplasms. miR-155-3p was found to be 
methylated in 36(27.0%) of non-MCL B-NHL, 24(53.3%) 
of T-NHL and 6(46.2%) of NK-cell lymphoma (Table 2), 
being more frequent in NK or T-NHL than B-NHL 
(p=0.003). In 72 NHL patients with frozen tissues, miR-
155-3p expression correlated inversely with methylation 
status, which was demonstrated by lower miR-155-3p 
expression in patients with miR-155-3p methylation than 
those without (Figure 5B) (p=0.024). Since both miR-
155-3p and miR-155-5p may be generated from the same 
precursor, expression of miR-155-5p was also studied in 
primary lymphoma samples in which both DNA & RNA 
were available. In contrast to miR-155-3p, there was no 
correlation between methylation status and expression 
of miR-155-5p (Figure 5C) (p=0.805). Therefore, DNA 
methylation was likely more important in regulating miR-
155-3p than miR-155-5p.
Overexpression of LT-β mediated by miR-155-3p 
methylation in primary NHL samples
To validate if methylation-mediated silencing 
of miR-155-3p could lead to overexpression of LT-β in 
primary MCL and other NHLs, the expression of LT-β was 
profiled in 34 patients with frozen specimens (Figure 5D). 
Indeed, specimens methylated for miR-155-3p showed 
higher LT-β expression compared with unmethylated 
specimens (p=0.043).
DISCUSSION
MCL is a rare entity, and comprised only 4% of 
all NHL in Hong Kong [3], hence only 31 cases were 
Figure 5: Overexpression of LT-β resulted from methylation-mediated silencing of miR-155-3p. (A) Representative cases 
showing methylation of miR-155-3p in 31 MCL and 133 non-MCL B-NHL, 45 T-NHL and 13 NK cell lymphoma biopsies using M-MSP. 
(B) Expression analysis of miR-155-3p a total of 72 NHL patient biopsies with or without methylations as detected by M-MSP. (C) Expression 
analysis of miR-155-5p the same 72 NHL patient biopsies with or without methylation as detected by M-MSP. (D) Expression analysis of 
LT-β in a random cohort (n=34) of NHL patient biopsies with or without miR-155-3p methylation.
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available for study here. Nonetheless, it is one of the 
largest analyses of microRNA methylation in MCL.
In this study, we have shown that miR-155-3p might 
be a novel tumor suppressive microRNA silenced in MCL 
due to the aberrant DNA methylation. However, miR-155-3p 
methylation is not restricted to MCL, and occurs in a 
wide array of other B-, T- and NK-cell lymphoma, hence 
suggesting a potential role in lymphomagenesis. This is 
consistent with our previous studies of miR-203, miR-124-1, 
miR-129-2 and miR-34a in NHLs, in which methylation of 
these tumor suppressive microRNAs occurred in multiple 
subtypes of NHLs [15-18]. Therefore, it is unlikely that 
methylation of miR-155-3p and these microRNAs are 
governed by the primary genetic translocation involved in the 
pathogenesis of disease. Other microRNAs downregulated 
by promoter DNA methylation includes miR-29a and 
miR-146a [19, 20]. In anaplastic lymphoma kinase 
expressing ALCL (ALK+ve ALCL) with t(2;5) translocation, 
miR-29a has been shown to target, and hence downregulate 
an anti-apoptotic protein, MCL-1 [19]. Similarly, miR-146a 
has been shown hypermethylated in NK/T-cell lymphoma, 
in which miR-146a was shown to target TRAF6 and hence 
downregulate NF-kB signaling [20].
Secondly, we have demonstrated miR-155-3p 
might function as a tumor suppressive microRNA in 
MCL cells by regulating the expression of LT-β. Indeed, 
the LT-β/LTβR axis has been shown to be important in 
physiological development of secondary lymphoid tissues. 
Interaction of LTα1β2 heterotrimer on immune cells with 
LTβR on stromal cell results in activation of non-canonical 
NF-kB signaling in stromal cells, with upregulation of 
adhesion molecules and secretion of chemokines for 
B- and T-cells, thereby attracting and retaining additional 
immune cells for the growth of lymph nodes and Peyer’s 
patches [21, 22]. Consistent with this notion, genetic 
knockout of LT-β or LTβR gene in mice has been shown to 
result in abnormal development or complete loss of lymph 
nodes and Peyer’s patches [23, 24]. On the other hand, an 
oncogenic role of LT-β/LTβR axis has been demonstrated 
in a mouse model, in which disease progression was 
associated tumor infiltration of LT-β-expressing B-cells, 
which interacted with LTβR-expressing tumor cells led 
to induction of IKK-α nuclear translocation and NF-kB 
activation [25]. Moreover, both ligand (LT-β) and receptor 
(LTβR) have been shown expressed in non-Hodgkin’s 
lymphoma cells including MCL [26], which potentially 
leads to constitutive activation of NF-kB signaling [27], 
suggesting a pathogenic role of the LT-β/LTβR axis in 
lymphomagenesis [28-30]. Using transgenic mouse 
model which displayed an aggressive B-cell lymphoma 
phenotype, LTβR signalling has been shown to collaborate 
with CCR7 signaling to maintain T-cell and B-cell 
localization within the lymphoid microenvironment 
hence contribution to lymphomagenesis. Inhibition of 
LTβR signaling by anti- LTβR antibody or knockdown 
of LTα impaired cell interaction between lymphoma cell 
and stromal cell, potentially by disrupting production of 
CCL19 and CCL21 by stromal cells which are ligands 
for CCR7 [31]. Furthermore, in this study, in primary 
lymphoma samples with frozen tissue, which included 
MCL and other lymphoma subtypes, LT-β expression 
correlated inversely with miR-155-3p methylation, hence 
consistent with LT-β as a direct target of miR-155-3p in 
multiple lymphoma subtypes in addition to MCL. Taken 
together, we have demonstrated a role of miR-155-3p 
methylation in the regulation of LT-β/LTβR axis in MCL 
and other NHL subtypes. Therefore, whether miR-155-3p 
methylation leads to dysregulation of NF-kB signaling in 
lymphomagenesis warrants further study.
In general, biogenesis of microRNA results in 
generation of two mature microRNAs, which are denoted 
as 5p and 3p, with different sequences from a same primary 
transcript [32]. Despite that majority of cancer studies 
focused on 5p microRNAs, recent studies demonstrated 
tumor suppressor property associated with several 
3p microRNAs including miR-574-3p, miR-219-2-3p  
and miR-338-3p in various solid cancers [33-37]. For 
instance, under-expression of miR-574-3p correlated 
with advanced pathological stage in prostate cancer. In 
cell lines, restoration of miR-574-3p in vitro induced 
apoptosis. Moreover, mice injected with prostate cancer 
cells overexpressed with miR-574-3p had retarded tumor 
growth compared to mice injected with untransfected 
tumor cells, testifying the tumor suppressive role of 
miR-574-3p [36]. Similarly, miR-219-2-3p has been 
shown to induce apoptosis, inhibit cell proliferation and 
metastasis in gastric cancer in vitro, and hence a bona fide 
tumor suppressor microRNA [34]. Moreover, in primary 
gastric cancer samples, downregulation of miR-219-2-3p  
associated with DNA methylation, also correlated with 
advanced tumor stage and grade. In addition, tumor 
suppressive function of miR-338-3p, downregulated in 
neuroblastoma, gastric and colorectal cancer, has been 
demonstrated in these tumors [33, 35, 37, 38]. Similar 
to miR-219-2-3p, miR-338-3p has been shown to be 
hypermethylated in gastric cancer, and restored miR-338-
3p expression induces apoptosis in vitro and inhibits tumor 
development in vivo [39]. Finally, miR-338-3p targets 
PREX2a, which plays an oncogenic role in activating AKT 
signaling in gastric cancer and neuroblastoma [33, 37]. 
Collectively, these studies illustrate the tumor suppressive 
function of 3p microRNAs through regulation of cell 
survival and signaling pathway.
In conclusion, we have identified miR-155-3p 
might be a novel tumor suppressive microRNA silenced 
in MCL due to promoter hypermethylation of its host 
gene MIR155HG, resulting in upregulation of LT-β. In 
addition to MCL, miR-155-3p methylation is prevalent 
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in other B-, T- and NK-cell NHLs, which correlated with 
over-expression LT-β, and hence potentially important in 
pathogenesis of lymphoma.
MATERIALS AND METHODS
Patient samples
Thirty-one primary MCL samples were obtained 
from the Department of Pathology from Queen Mary 
Hospital since 1997. Diagnosis of MCL was based on 
morphologic criteria. Immunophenotyping was performed 
on cryostat sections or paraffin sections with standard 
immunoperoxidase technique. Paraffin sections of formalin- 
or B5-fixed tissue were stained with hematoxylin-eosin to 
confirm the diagnosis of lymphoma and examined for the 
expression of B- and T-cell markers. The panel of antibodies 
used included CD3 (Leu4; Becton Dickinson, San Jose, CA), 
CD3 (polyclonal; Dako, Glostrup, Denmark), CD5 (Dako), 
CD10 (J5; Coulter, Hialeah, FL), CD19 (Leu 12; Becton 
Dickinson), CD20 (L26; Dako), CD22 (Dako), CD23 
(Dako), and cyclin D1 (Zymed, San Francisco, CA). All 31 
cases of MCL were classic-variant, with the phenotype of 
CD5+, CD10−, and CD23−, and immunoreactive for cyclin 
D1[40]. Moreover, an additional 191 diagnostic lymph 
node biopsies were obtained from five major hospitals 
(Queen Mary Hospital, Pamela Youde Nethersole Eastern 
Hospital, United Christian Hospital, Kwong Wah Hospital 
and Princess Margaret Hospital) including 133 B-NHL 
other than MCL, 45 T-NHL and 13 NK-cell lymphomas. 
Diagnoses of NHLs were made according to WHO 
(World Health Organization) classification [41]. Among 
the non-MCL B-NHL cases, 57 each were diffuse large 
B-cell lymphoma (DLBCL) and follicular lymphoma (FL) 
respectively, 6 cases were Burkitt-like lymphoma (BL), 
5 cases were mucosa-associated lymphoid tissue lymphoma 
(MALT), and 8 were marginal zone B-cell lymphoma 
(MZBCL). Of the 45 T-NHL cases, 21 were classified as 
peripheral T-cell lymphoma (PTCL) while 24 were classified 
as angioimmunoblastic T-cell lymphoma (AITL). Formalin-
fixed, paraffin-embedded (FFPE) tonsils from 15 healthy 
individuals undergoing tonsillectomy were also collected. 
Moreover, frozen tissues, in which both DNA and RNA were 
extracted, were available in 72 patients including 4 MCLs, 
5 BLs, 34 DLBCLs, 8 FLs, 7 MZBCLs and 14 AITLs. 
Informed consents were obtained from all patients and the 
study was approved by Institutional Review Board of Queen 
Mary Hospital.
Plasmid constructs
The LT-β 3′-UTR cDNA sequence (NM_002341.1 
or NM_009588.1) of a total of 157bp flanking the seed 
region binding site of mature miR-155-3p was cloned into 
SacI and XbaI restriction sites of pmirGLO luciferase 
reporter (Promega, Madison, WI, USA), encoding both 
firefly luciferase for reporter signal and renilla luciferase 
for assay normalization. A LT-β 3′-UTR mutant control 
construct, in which the sequence complementary to the 
seed region binding site of miR-155-3p was deleted, 
was generated using QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) 
following manufacturer’s instruction. Primer sequences 
used were listed in Table 1.
Cell culture
Four MCL cell lines (REC-1, GRANTA-519, MINO 
& JEKO-1) were used in this study. REC-1 was kindly 
provided by Prof Raymond Lai (Department of Laboratory 
Medicine and Pathology, University of Alberta and 
Cross Cancer Institute). Other cell lines were purchased 
from Deutsche Sammlung von Mikroogranismen und 
Zellkulturen (DSMZ) (Braunschweig, Germany). All cell 
lines were maintained in RPMI-1640 supplemented with 
15% fetal bovine serum, 50U/mL of penicillin and 50ug/
mL streptomycin in a humidified atmosphere of 5% CO2 
at 37oC.
Hypomethylating treatment
JEKO-1, MINO and REC-1 were seeded at a 
density of 1x106 cells/ml and cultured with 0.5–1.5uM of 
5-aza-2′-deoxycytidine (5-azadC) (Sigma–Aldrich) for 
3-5 days as previously described [15, 18, 42].
DNA and RNA extraction
DNA isolation from frozen patient biopsies was 
performed by automated DNA extraction system (DNA 
Tissue Kit from Qiagen) while FFPE fixed NHL samples 
and the 15 normal tonsils were extracted with QIAamp 
DNA FFPE Tissue Kit (Qiagen). For cultured cell lines, 
DNA extraction was performed using DNA Blood Mini 
(Qiagen). Extractions of microRNA were performed 
by using mirVanaTM miRNA Isolation Kit (Ambion) 
following manufacturer’s instruction.
Microarray analysis
Total RNA isolated from MINO and JEKO-1 before 
and after 5-azadC treatment were converted into cDNA 
by MegaplexTM RT Primers and TaqMan® MicroRNA 
Reverse Transcription Kit. cDNA was pre-amplified 
using MegaplexTM PreAmp Primer and loaded onto 
384-well format Taqman® human microRNA array A V2.0 
& B V3.0. Real-time PCR was performed on 7900HT 
Real-Time PCR system and raw data were analyzed 
normalizing to mean of three endogenous controls 
(U6snRNA, RNU44 and RNU48). Relative microRNA 
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Table 1: Primer sequences for Methylation-specific PCR (MSP), Pyrosequencing, Real-time PCR 
and luciferase reporter assay
Forward Primer Reverse Primer Sequencing Primer
Methylation-specific PCR (MSP)
M-MSP TAG TCG ATT GAA AGT TCG GGC CCT TTC TCG TAA ATC ATT ACG  
U-MSP TTT TAG TTG ATT GAA AGT TTG GGT
TTT CCC TTT CTC ATA AAT 
CAT TAC A  
Quantitative Bisulfite Pyrosequencing
GGT TTT TTG TAA GGA GAG AGT 
AGA GAT
AAT ATT TTC CCC TTT CCC 
TTT CT
ATA TTT TTG TTA TTT 
AGT TGT AAG A
Real-time PCR
LT-β GGT TTC AGA AGC TGC CAG AG TTC AGC GGA GCG CCT AT  
GAPDH ACC ACA GTC CAT GCC ATC ACT TCC ACC ACC CTG TTG CTG TA  
Luciferase Reporter Plasmid
LT-β Wild-type CGA GCT CGG GGA ATA TGA GTG CGT GGT G
GCT CTA GAG CTC TAG ATT 
TAT CGG CAG CAC TGA 
AGC
 
LT-β Deletion CCC ATG GCA GTG GGA AAA AGA CTG TTT GGA AAT TG
CAA TTT CCA AAC AGT 
CTT TTT CCC ACT GCC ATG 
GG
 
Table 2: Frequency of miR-155-3p methylation in MCL and different types of NHLs as detected 
by MSP
Disease Subtype Sample Size Frequency Methylated (%)
Mantle cell lymphoma (MCL) 31 6 (19.4%)
Other B-NHL 133 36 (27.0%)
Diffuse large B-cell lymphoma (DLBCL) 57 18 (31.5%)
Follicular lymphoma (FL) 57 11 (19.3%)
Burkitt -like (BL)lymphoma 6 2 (33.3%)
Mucosa-associated lymphoid tissue lymphoma (MALT) 5 2 (40.0%)
Marginal Zone B-cell lymphoma (MZBCL) 8 3 (37.5%)
T-NHLs 45 24 (53.3%)
Peripheral T-cell Lymphoma (PTCL) 21 11 (52.4%)
Anaplastic T-cell lymphoma (AITL) 24 13 (54.2%)
NK cell lymphoma 13 6 (46.2%)
levels were determined by ΔΔCt using endogenous 
controls and untreated controls using SDS 2.4 and RQ 
manager 1.2. All experimental procedures and analyses 
were performed according to manufacturer’s instruction, 
using reagents, system and softwares acquired from 
Applied Biosystems (Foster City, USA). Candidate 
microRNAs were selected according to the following 
criteria: (1) upregulated by ≥ 2.5-fold in either or both 
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cell lines after 5-azadC treatment, (2) localized outside 
the X chromosome or imprinted regions (e.g. 14q32) due 
to potential methylation in normal tissues, (3) presence 
of CpG island, (4) absence of methylation in healthy 
controls, and (5) showed complete methylation in any of 
the MCL cell lines.
Methylation-specific polymerase chain reaction 
(MSP)
DNA samples were treated to convert unmethylated 
cytosine into uracil by EpiTect Bisulfite Kit (Qiagen). As 
miR-155-3p is an exonic microRNA localized to the third 
exon of and regulated by the same promoter of its host 
gene, MIR155HG (previously known as B-cell integration 
cluster, BIC), primers used for methylated-MSP (M-MSP) 
and unmethylated-MSP (U-MSP) were designed at CpG 
island upstream of its host gene of MIR155HG (Table 1) 
[43, 44]. All MSPs were conducted as previously described 
[15, 18, 42]. DNA from 6 normal peripheral blood and 15 
normal tonsils were used as unmethylated controls while 
an enzymatically methylated control DNA purchased from 
CpGenome Universal Methylated DNA (Chemicon) was 
used as methylated control.
Quantitative bisulfite pyrosequencing
Using bisulfite converted DNA as template, 
a segment of promoter region overlapping with the 
amplicon of the MSP was amplified with a primer set, 
which amplified both methylated and unmethylated 
DNA sequences in an unbiased manner. Subsequently, 
a stretch of DNA containing 6 consecutive CpG 
dinucleotides on the PCR products was pyrosequenced 
and quantified as previously described [17]. Quantitative 
DNA methylation analysis was carried out on a PSQ 
96MA system and results were analyzed using PyroQ-
CpG 1.0.9. Primer sequences for PCR amplification and 
pyrosequencing were designed using PyroMark Assay 
Design 2 (Table 1).
RT-qPCR
For expression analysis of mature miR-155-3p or 
miR-155-5p, RNA was reverse transcribed into cDNA by 
TaqMan® MicroRNA Reverse Transcription Kit, followed 
by RT-qPCR using TaqMan® MicroRNA Assays (Applied 
Biosystems). RNU48 was used as endogenous control as 
previously described [15, 18, 42]. Conventional RT-qPCR 
was employed for the analysis of LT-β, using QuantiTect 
Reverse Transcription Kit (Qiagen) and iQTM SYBR® 
Green Supermix (Bio-Rad) according to manufacturer’s 
instructions. GAPDH was included as endogenous control. 
For each sample, signals from triplicate wells were recorded 
and calculated as mean of Ct for analysis. All data were 
analyzed adopting the 2−ΔΔCt or 2−ΔCt method and primer 
sequences for LT-β and GAPDH were listed in Table 1.
miR-155-3p overexpression
Exponentially growing cells at a density of 1x106 
cells/ml were transfected with 50nM of either miR-155-3p 
mimic oligonucleotide or a scramble negative control 
(Ambion), using Lipofectamine 2000 transfection reagent 
(Invitrogen) according to manufacturer’s instruction.
Trypan blue exclusion assay
Viable live cells were distinguished by the 
exclusion of trypan blue staining as observed under 
microscope. Five random microscopic fields were 
counted and percentage of viable cells was calculated as 
×           100%
total number of live cells per microscopic field
total number of cells per microscopic field
Cell cycle analysis
Harvested cells were fixed and permeabilized with 
Cytofix/Cytoperm buffer (BD Biosciences) followed by 
80% ethanol at -20°C for 2 hours. Cells were then washed 
and stained with 7-AAD (BD Bio sciences) according 
to manufacturer’s instruction. Fluorescence readings 
were acquired using a BD LSR Fortessa analyser (BD 
Biosciences). Quantitation of singlets at G1, S, G2 and 
M phases in addition to Sub-G1 fractions was performed 
using FlowJo 7.6.1 (Tree Star, Inc).
Flow cytometric staining
Harvested cells of 1x106 were washed with 
PBS followed by fixation and permeabilization using 
Cytofix/Cytoperm buffer (BD Biosciences) according 
to manufacturer’s instruction. Cells were then stained 
with anti-LT-β rabbit polyclonal antibody at a final 
concentration of 4ng/mL (Abcam, Cat# ab64835) 
followed by secondary incubation with Alexa Fluor 
594 goat anti-rabbit IgG at a concentration of 10ng/mL 
(Molecular Probe, Cat# A11072), as recommended by 
manufacturer.
Luciferase reporter assay
Wild-type or mutant LT-β 3′-UTR luciferase reporter 
construct was co-transfected with miR-155-3p oligo mimic 
or scramble negative control (Ambion) into HeLa cells 
(kindly provided by Dr Zou, at Department of Medicine, 
The University of Hong Kong) using Lipofectamine 
2000 (Invitrogen) [45]. After 24h, the luminescent signal 
produced by Dual-Glo Luciferase Assay system (Promega) 
was measured using FLUOstar OPTIMA (BMG Labtech), 
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following the manufacturer’s instructions. A triplicate 
reading was recorded for each exogenous transfection.
Statistical analysis
Mean expression of microRNAs or genes in 
methylated and unmethylated NHL cases were compared 
by the Student’s t-test. Frequency of miR-155-3p 
methylation in different NHL subtypes was compared 
by X2 test. The means of three independent 5-azadC 
treatments or exogenous transfections were compared by 
Student’s t-test. All p-values were 2-sided and statistical 
significance was defined as p-value < 0.05.
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